Logo image of NEXI

NEXIMMUNE INC (NEXI) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:NEXI - US65344D2080 - Common Stock

3.93 USD
+1.62 (+70.13%)
Last: 7/11/2024, 8:02:56 PM
3.45 USD
-0.48 (-12.21%)
After Hours: 7/11/2024, 8:02:56 PM
Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to NEXI. NEXI was compared to 529 industry peers in the Biotechnology industry. The financial health of NEXI is average, but there are quite some concerns on its profitability. NEXI does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

NEXI had negative earnings in the past year.
In the past year NEXI has reported a negative cash flow from operations.
In the past 5 years NEXI always reported negative net income.
NEXI had a negative operating cash flow in each of the past 5 years.
NEXI Yearly Net Income VS EBIT VS OCF VS FCFNEXI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 -20M -40M -60M

1.2 Ratios

NEXI has a worse Return On Assets (-287.63%) than 94.09% of its industry peers.
NEXI has a worse Return On Equity (-871.66%) than 82.61% of its industry peers.
Industry RankSector Rank
ROA -287.63%
ROE -871.66%
ROIC N/A
ROA(3y)-164.95%
ROA(5y)-153.9%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
NEXI Yearly ROA, ROE, ROICNEXI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 0 200 -200 -400 -600

1.3 Margins

NEXI does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
NEXI Yearly Profit, Operating, Gross MarginsNEXI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022

More info and screens

5

2. Health

2.1 Basic Checks

Compared to 1 year ago, NEXI has more shares outstanding
The number of shares outstanding for NEXI has been increased compared to 5 years ago.
There is no outstanding debt for NEXI. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
NEXI Yearly Shares OutstandingNEXI Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 200K 400K 600K 800K 1M
NEXI Yearly Total Debt VS Total AssetsNEXI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M

2.2 Solvency

NEXI has an Altman-Z score of -43.67. This is a bad value and indicates that NEXI is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -43.67, NEXI is doing worse than 94.61% of the companies in the same industry.
There is no outstanding debt for NEXI. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -43.67
ROIC/WACCN/A
WACCN/A
NEXI Yearly LT Debt VS Equity VS FCFNEXI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 0 20M -20M 40M -40M 60M 80M

2.3 Liquidity

A Current Ratio of 1.30 indicates that NEXI should not have too much problems paying its short term obligations.
NEXI has a Current ratio of 1.30. This is amonst the worse of the industry: NEXI underperforms 85.04% of its industry peers.
A Quick Ratio of 1.30 indicates that NEXI should not have too much problems paying its short term obligations.
NEXI has a Quick ratio of 1.30. This is amonst the worse of the industry: NEXI underperforms 82.96% of its industry peers.
Industry RankSector Rank
Current Ratio 1.3
Quick Ratio 1.3
NEXI Yearly Current Assets VS Current LiabilitesNEXI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M

More info and screens

1

3. Growth

3.1 Past

NEXI shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -245.95%.
EPS 1Y (TTM)-245.95%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%73.25%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

NEXI is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 25.96% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y99.01%
EPS Next 2Y41.34%
EPS Next 3Y25.96%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
NEXI Yearly Revenue VS EstimatesNEXI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2028 2029 2030 5M 10M 15M 20M
NEXI Yearly EPS VS EstimatesNEXI Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 -20 -40 -60

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

NEXI reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year NEXI is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
NEXI Price Earnings VS Forward Price EarningsNEXI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
NEXI Per share dataNEXI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -20 -40 -60

4.3 Compensation for Growth

A more expensive valuation may be justified as NEXI's earnings are expected to grow with 25.96% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y41.34%
EPS Next 3Y25.96%

More info and screens

0

5. Dividend

5.1 Amount

NEXI does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

NEXIMMUNE INC

NASDAQ:NEXI (7/11/2024, 8:02:56 PM)

After market: 3.45 -0.48 (-12.21%)

3.93

+1.62 (+70.13%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-13 2024-05-13/amc
Earnings (Next)08-07 2024-08-07/amc
Inst Owners0.79%
Inst Owner Change0%
Ins Owners280.8%
Ins Owner Change0%
Market Cap5.38M
Revenue(TTM)N/A
Net Income(TTM)-25.86M
Analysts82.86
Price Target2.04 (-48.09%)
Short Float %0.01%
Short Ratio0
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.81
P/tB 1.81
EV/EBITDA N/A
EPS(TTM)-66.25
EYN/A
EPS(NY)-0.15
Fwd EYN/A
FCF(TTM)-15.75
FCFYN/A
OCF(TTM)-15.74
OCFYN/A
SpS0
BVpS2.17
TBVpS2.17
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -287.63%
ROE -871.66%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-164.95%
ROA(5y)-153.9%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 0.99%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.3
Quick Ratio 1.3
Altman-Z -43.67
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)178.7%
Cap/Depr(5y)258.04%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-245.95%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%73.25%
EPS Next Y99.01%
EPS Next 2Y41.34%
EPS Next 3Y25.96%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y56.44%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y36.38%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y34.07%
OCF growth 3YN/A
OCF growth 5YN/A

NEXIMMUNE INC / NEXI FAQ

What is the fundamental rating for NEXI stock?

ChartMill assigns a fundamental rating of 2 / 10 to NEXI.


What is the valuation status of NEXIMMUNE INC (NEXI) stock?

ChartMill assigns a valuation rating of 1 / 10 to NEXIMMUNE INC (NEXI). This can be considered as Overvalued.


How profitable is NEXIMMUNE INC (NEXI) stock?

NEXIMMUNE INC (NEXI) has a profitability rating of 0 / 10.